HCW Biologics Inc. (HCWB)

MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflammation and disease, today announced the pricing of its follow-on offering of an aggregate of 2,477,292 units at a purchase price of $0.6055 per unit priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant, each to purchase one share of common stock. The warrant will have an exercise price of $0.6055 per share, will be exercisable upon shareholder approval, and will expire on the five-year anniversary from such date of shareholder approval. The shares of common stock (or pre-funded warrants) and the warrant comprising the units are immediately separable and will be issued separately in this offering. The closing of the offering is expected to occur on or about February 19, 2026, subject to the satisfaction of customary closing conditions.

HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with HCW Biologics' TRBC drug development platform Initiation of Phase 1 clinical study expected in the first half of 2027 HCW Biologics retains royalty-free option to reclaim the rights to the Americas territory MIRAMAR, Fla., Feb. 13, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflammation and disease, and WY Biotech Co., Ltd.

HCW Biologics (NASDAQ: HCWB - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Valuation and Earnings This table compares HCW Biologics and

HCW Biologics (NASDAQ: HCWB - Get Free Report) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability. Analyst Recommendations This is a summary of current

HCW Biologics Inc. (NASDAQ: HCWB - Get Free Report) traded down 7.1% during mid-day trading on Monday. The company traded as low as $1.96 and last traded at $1.97. 20,121 shares traded hands during trading, a decline of 97% from the average session volume of 784,371 shares. The stock had previously closed at $2.12. Wall

First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind immunotherapeutic for autoimmune and pro-inflammatory diseases MIRAMAR, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced the first patient was dosed at The Ohio State University Wexner Medical Center for the Company-sponsored, multi-center first-in-human clinical trial to evaluate HCW9302 in patients with alopecia areata (NCT07049328).

MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2025.

Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors

MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

Watch the "What This Means" video here

Wugen closed a $115 million equity financing led by  Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, congratulates Wugen, Inc. (“Wugen”) on its recently announced $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management, and other leading life sciences investors.

Lead product candidate will be advanced to late IND-enabling studies  to prepare for clinical trials for evaluation in the treatment of solid tumors

HCW Biologics Inc. HCWB stock is trading higher on Monday, with a session volume of 10.85 million compared to the average volume of 132.51K as per data from Benzinga Pro.

Company's pembrolizumab-based immune checkpoint inhibitor exhibited success  against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern University  on September 12, 2025, in Fort Lauderdale, Florida MIRAMAR, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have successfully developed second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly for pancreatic and ovarian cancer, using its novel proprietary TRBC product discovery and development platform technology.

MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025.

Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated